Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.80.

The success of an ongoing pilot programme offering RSV vaccination to newborn infants provides hope in tackling the ...

GlaxoSmithKline has found a replacement for ... His time at Pfizer has coincided with the spectacular success of its BioNTech-partnered mRNA vaccine for COVID-19 – Comirnaty – and as GSK ...

GlaxoSmithKline Pharmaceuticals Limited is ... Cefspan (Cefixime - oral antibiotic) was relaunched with good success. Other branded generics launched during the year were Modvate 3 cream ...

MTN Nigeria CEO Karl Toriola has defended recent tariff hikes by mobile network operators, stating they are essential for the “survival” of the telecoms industry in Nigeria, despite significant ...

Westmorland and Furness Council has approved a planning application from applicants, named as Ms and Mr A and D Atkinson and Robinson, to allow indoor sport, fitness and the provision of medical ...

Similarly, whilst GlaxoSmithKline’s origins can be traced ... aspirin around the turn of the 20th century, one of the most successful pharmaceuticals ever at that point. The unregulated nature ...